| PVSRIPO | |
|---|---|
Virus classification 
| |
| (unranked): | Virus |
| Realm: | Riboviria |
| Kingdom: | Orthornavirae |
| Phylum: | Pisuviricota |
| Class: | Pisoniviricetes |
| Order: | Picornavirales |
| Family: | Picornaviridae |
| Genus: | Enterovirus |
| Species: | |
| Strain: |
PVSRIPO
|
PVSRIPO, or PVS-RIPO, is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University.
PVS-RIPO consists of a genetically modified nonpathogenic version of the oral poliovirus Sabin type 1. The internal ribosome entry site (IRES) on the poliovirus was replaced with the IRES from human rhinovirus type 2 (HRV2), to avoid neurovirulence. Once administered, the virus enters and begins replicating within cells that express CD155/Necl5, which is an onco-fetal cell adhesion molecule that is common across solid tumors.
A website at Duke University describes many of properties of PVSRIPO, and historical background about using viruses to oppose cancer. According to that website,
The FDA approved clinical trials with PVS-RIPO in brain tumor patients recently. Since May 2012, five brain tumor patients have been treated. Remarkably, there have been no toxic side effects with PVS-RIPO whatsoever, even at the highest possible dose (10 billion infectious virus particles).
The potential value of PVSRIPO was the focus of a 2015 story on 60 Minutes.
In May 2016, the US Food and Drug Administration granted it breakthrough therapy designation for glioblastoma.